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Multivariate analysisAlthough age is thought to correlate with the prognosis of glioma patients, themost appropriate age-group clas-
siﬁcation standard to evaluate prognosis had not been fully studied. This study aimed to investigate the inﬂuence
of age-group classiﬁcation standards on the prognosis of patients with high-grade hemispheric glioma (HGG).
This retrospective study of 125 HGG patients used three different classiﬁcation standards of age-groups (≤50
and N50 years old, ≤60 and N60 years old, ≤45 and 45–65 and ≥65 years old) to evaluate the impact of age on
prognosis. The primary end-point was overall survival (OS). The Kaplan–Meier method was applied for univar-
iate analysis and Cox proportional hazards model for multivariate analysis. Univariate analysis showed a signif-
icant correlation between OS and all three classiﬁcation standards of age-groups as well as between OS and
pathological grade, gender, location of glioma, and regular chemotherapy and radiotherapy treatment. Multivar-
iate analysis showed that the only independent predictors of OS were classiﬁcation standard of age-groups ≤50
and N50 years old, pathological grade and regular chemotherapy. In summary, themost appropriate classiﬁcation
standard of age-groups as an independent prognostic factor was ≤50 and N50 years old. Pathological grade and
chemotherapy were also independent predictors of OS in post-operative HGG patients.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Gliomas are themost frequently occurring primary tumors of the cen-
tral nervous system [1]. Grade III and grade IV tumors, which are called
high-grade gliomas (HGGs) have a poor prognosis and no effective ther-
apeutic strategies [2]. Despite tremendous progress in this ﬁeld over the
past decade, the median survival in patients with glioblastoma
multiforme (GBM) is approximately 1 year [3]. The current standard of
care forHGGs includes a combinationof surgery andadjuvant focal, exter-
nal beam radiation, and is largely palliative in nature [4]. Some challenges
with the current standard of care therapy include the ﬁndings that suble-
thal doses of radiation promoted the migration of glioma cells, leading to
locoregional relapses [5]. Addition of a daily oral dose of the chemothera-
peutic agent, temozolamide (TMZ) signiﬁcantly improved the survival
rate from 6%–10% compared with patients treated with adjuvant radio-
therapy alone [6,7]. However, development of drug resistance andCI, conﬁdence interval; EGFR,
ltiforme; HGG, high-grade glio-
, Karnofsky Performance Scale;
, overall survival; SD, standard
lial growth factor A.
y, The First Afﬁliated Hospital of
05, Fujian, China.
. This is an open access article undertoxicity is the major drawbacks with this chemotherapy regimen [8].
Moreover, tumor recurrence is almost inevitable even after a therapeutic
strategy using a combination of the most extensive tumor resection pos-
sible along with post-operative adjuvant radiochemotherapy [3,9–11].
A number of studies have investigated the factors predicting tumor
recurrence and survival in HGG patients. Some molecular markers
which have been used for prognostic purposes as well as to identify
glioma subtypes include 1p/19q chromosomal codeletion, isocitrate de-
hydrogenase (IDH) mutations, methylation of O-6-methylguanine-
DNA-methyltransferase promoter (MGMT), ampliﬁcation of the epider-
mal growth factor receptor (EGFR) gene, and overexpression of vascular
endothelial growth factor A (VEGF-A) [12–14]. Additionally, age, histo-
pathology,molecular pathology and imaging, the extent of tumor resec-
tion and Karnofsky Performance Scale (KPS) scores have been shown to
be correlated with prognosis [15–17].
Themedian age of onset of HGG is 64 years old and patients N70 years
old comprise almost 20% of all newly diagnosed glioblastoma cases in the
United States [18]. Elderly patients aremore prone to complications, their
ability to tolerate surgery, chemotherapy and radiotherapy is inferior to
that of young patients, and they are generally excluded frommost clinical
trials. Elderly patients have also been shown to express higher levels of
VEGF compared with younger patients, and this has been suggested to
contribute to the fact that they have a worse prognosis than young
patients [19]. A number of studies have evaluated age as a prognosticthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Distribution of demographic and clinical characteristics and estimated risk of death in
patients with gliomas of cerebral hemisphere.
Characteristics n (%) HRb (95% CI) p
Gender
Male 78 (62.4) 1.00
Female 47 (37.6) 0.61 (0.39–0.97) 0.036
Chemotherapy
No 38 (30.4) 1.00
Irregular 53 (42.4) 0.62 (0.38, 1.01) 0.055
Regular 34 (27.2) 0.40 (0.22, 0.71) 0.002
Radiotherapy
No 60 (48.0) 1.00
Yes 65 (52.0) 0.51 (0.33, 0.79) 0.002
Grade
III 56 (44.8) 1.00
IV 69 (55.2) 3.06 (1.93, 4.86) b0.001
Karnofsky Performance Scalea 71.8 (10.4) 0.98 (0.97, 1.00) 0.021
Laterality
Left 68 (54.4) 1.00
Right 48 (38.4) 0.87 (0.56, 1.36) 0.544
Location
Lobar 103 (82.4) 1.00
Non-lobar 18 (14.4) 1.87 (1.06, 3.31) 0.030
Size (cm3)a 67.1 (46.9) 1.00 (0.99, 1.00) 0.504
Age group 1
≤45 years 54 (43.2) 1.00
46–64 years 56 (44.8) 2.21 (1.37, 3.57) 0.001
≥65 years 15 (12.0) 3.05 (1.57, 5.94) 0.001
Age group 2
≤50 years 66 (52.8) 1.00
N50 years 59 (47.2) 2.47 (1.59, 3.82) b0.001
Age group 3
≤60 years 98 (78.4) 1.00
N60 years 27 (21.6) 2.77 (1.68, 4.55) b0.001
Abbreviation: HR = hazard ratio; CI = conﬁdence interval.
a Data were shown as mean (standard deviation).
b HR and 95% CI were calculated by Cox regression analysis.
149J.-W. Chen et al. / Journal of the Neurological Sciences 356 (2015) 148–152factor. A single institutional review of 70 patients with intracranial ana-
plastic oligodendroglioma showed that patients b50 years old had a sig-
niﬁcantly longer median survival compared with patients N50 years old
[15]. Other studies also demonstrated that in addition to KPS scores, ex-
tent of surgery, and histological characteristics, agewas a signiﬁcant prog-
nostic factor [20,16,21]. In contrast, data fromsome studies suggested that
age was not a prognostic factor in glioma patients [17,22].
Since there was a signiﬁcant variation in the age classiﬁcation stan-
dards used in the different studies, we hypothesized that the conﬂicting
data fromprevious studiesmay be due to differences in the age classiﬁca-
tion standards. In this study, we aimed to evaluate the inﬂuence of dif-
ferent classiﬁcation standards of age-groups on the prognosis of patients
with high-grade hemispheric glioma.
2. Patients and methods
2.1. Clinical data
This study gathered clinical and imaging data from a total of 125 pa-
tients with high-grade hemispheric glioma who received surgery and
then were pathologically veriﬁed at the Division of Neurosurgery of
the First Afﬁliated Hospital of Fujian Medical University between June
2002 and June 2012. The extent of resection was determined using
post-operative enhanced MRI within 3 days of surgery. The inclusion
criteria are as follows: 1) presence of fully-resected high-grade hemi-
spheric glioma under the operating microscope, 2) availability of clear
radio-chemotherapy data and follow-up data, and 3) availability of
clear pathological data. The exclusion criteria are as follows: 1) presence
of infratentorial glioma, brain glioma or WHO grade I, II glioma, 2) ab-
sence of histopathological data and 3) absence of follow-up data.
Patients who underwent partial resection or biopsy were also excluded
(partial resection is indicated by the presence of an enhancing lesion
which occupies more than 80% of the surgical cavity). Most of the
study patients received post-operative radio-chemotherapy. The che-
motherapy treatment plan included ≥4 cycles of temozolomide (TMZ;
150 mg/M2KOF/day); radiation therapy, with a single dose of 2 Gy up
to a total dose of 54–58 Gy was concomitantly administered after the
second cycle of chemotherapy. The irradiated area covered the operat-
ing region plus a safety margin of 2 cm. Chemotherapy was carried
out at our clinical center, while radiotherapywas performed at different
clinical centers. The accumulated numbers of irradiation ranged from 0
to 30, and a single irradiation dose to an individual ranged from 0 to
2.65 Gy. Pathological gradeswere based on the 2007WHO classiﬁcation
standard of brain tumors [23].
Classiﬁcation of patients by age was based on three different
methods: (1) ≤50 or N50 age-groups as previously described by Yang
et al. [15]; (2) ≤60 or 60 age-groups as previously described byAllahdini
et al. [17]; and (3) ≤45, 45–65, or ≥65 age-groups as previously
described by Lacroix et al. [24].
The primary outcome was overall survival (OS), which was deﬁned
as the time period from the ﬁrst surgery until death or until the ﬁnal
follow-up visit. The study was terminated on June 1st, 2012. A total of
39 patients were still alive at the end of follow-up and 86 patients had
died (28 grade III cases, 58 grade IV cases).
Informed consentwas obtained fromall studypatients and the study
was approved by the medical ethics committee of the Fujian Medical
University.
2.2. Statistical analyses
Categorical variables were shown as number and percent, while con-
tinuous variables were shown asmean and standard deviation (SD). Sub-
jects were followed-up from the time of surgical operation until death or
until the last follow-up. Kaplan–Meier survival analyses were used to es-
timate the probability of survival with different age-groups as cut-off
points. Log-rank tests were performed to compare survival rates amongage-groups. Cox proportional hazard regression models were performed
to calculate hazard ratio (HR) with 95% conﬁdence interval (CI) for risk
of death. In order to identify signiﬁcant effects of each variable with mul-
tiple categories, tests of global null hypothesis by likelihood ratio tests
were further used by comparing intercept-only model to the model
with the variable being tested.
The multivariate Cox regression model included signiﬁcant variables
identiﬁed by univariate analysis, except for age-groups. Subsequently, a
backward selection procedure was performed; variables with p-values
of less than 0.05 were included in Model I. After the multivariate Cox re-
gression model (Model I) was constructed, three separate models were
created by applying age-groups with different cut-off points. These in-
cluded Model II: ≤45 years, 46–64 years, and ≥65 years; Model III:
≤50 years and N50 years; and Model IV: ≤60 years and N60 years. The
Akaike information criterion (AIC) was calculated to determine the best
cut-off point of age among three multivariate models. The model with
the lowest AIC valuewas considered as the bestmodel. All statistical anal-
yses were performed with SAS software version 9.2 (SAS Institute Inc.,
Cary, NC). A two-tailed p b 0.05 indicated statistical signiﬁcance.
3. Results
The study population comprised 78 males (62.4%) and 47 (37.6%)
females. The ratio of males to females was 1.66:1. The age range of the
study subjects was 16–78 and the mean age was 48.1 years (SD =
14.6 years). Analysis of age of the study patients showed that 43.2% of
the subjects was under 45 years old, 47.2% was N50 years old, and
21.6% of subjects was N60 years old (Table 1). A total of 38 patients
did not receive any chemotherapy, 53 patients (42.4%) received irregular
chemotherapy, and 34 patients (27.2%) received regular chemotherapy.
Sixty patients did not receive any radiotherapy and 65 patients received
radiotherapy. There were 56 patients classiﬁed as WHO grade III, and 69
150 J.-W. Chen et al. / Journal of the Neurological Sciences 356 (2015) 148–152patients classiﬁed asWHO grade IV. All 56 patients with grade III gliomas
enrolled in this studywere diagnosedwith anaplastic astrocytoma. Ama-
jority of patients had left-side gliomas located in the lobes (58.6% for
laterality and 85.1% for location). The average size of glioma was
67.1 cm3 (SD= 46.9 cm3) (Table 1).
The mean follow-up time was 23.2 months (SD = 21.9 months). A
total of 86 subjects (68.8%) died during the study period. The median
survival time was 19 months and the one-year and two-year survival
rates were 64.8% and 40.0%, respectively (data not shown). Survival
rates were analyzed in the different age-groups using Kaplan–Meier
curves (Fig. 1). Regardless of the deﬁnition of age groups, results of
log-rank test consistently showed that patients in the older age-group
had signiﬁcantly lower survival rates compared with patients in the
younger age-groups (all p b 0.001). Kaplan–Meier survival curves
were also plotted for demographic and clinical characteristics. We
showed that survival outcomes were better in patients who were fe-
male, had received regular chemotherapy and radiotherapy, had lower
grade of tumor based on WHO classiﬁcation, or had lobar-involved gli-
oma (Fig. S1).Fig. 1. Kaplan–Meier survival curves according to age-groups (A) age group 1 classiﬁca-
tion: ≤45 years, 46–64 years, and ≥65 years; (B) age group 2 classiﬁcation: ≤50 years
and N50 years; and (C) age group 3 classiﬁcation: ≤60 years and N60 years. Log-rank
tests were performed to compare survival rates among age-groups.We analyzed the effect of age on OS using multivariate Cox regres-
sionmodels of the age groupswith different cut-off points. Since gender
and radiotherapy were not signiﬁcant after backward selection proce-
dure was performed, we excluded them from our multivariate analysis.
Hazard ratio was used as the index of risk of death, deﬁned by the ratio
of risk of death in older patients to that in younger patients. When age
was not considered in the analysis (Model I), we showed that regular
chemotherapy (HR = 0.45 and 95% CI = 0.25–0.82, p = 0.009) and a
higher Karnofsky Performance scale (KPS) score were both associated
with a decreased risk of death (HR = 0.97 and 95% CI = 0.96–0.99,
p b 0.001). Additionally, subjects with grade IV gliomas of the cerebral
hemisphere had a higher risk of death compared with those with a
lower grade (HR = 3.71 and 95% CI = 2.26–6.10) (Table 2).
Models II, III, and IV were constructed using three deﬁnitions of age
respectively. After taking clinical characteristics into consideration, we
showed that a higher age was signiﬁcantly associated with a higher
risk of death, regardless of the deﬁnition of age (all p b 0.05). Older pa-
tients had a two-to three-fold higher risk of death comparedwith youn-
ger patients across all three age-groups (age group 1: HR=2.11 for 46–
64 years vs. ≤45 years and 3.28 for ≥65 years vs. ≤45 years; age group 2:
HR = 2.74, 95% CI = 1.72–4.35; age group 3: HR = 2.57, 95% CI =
1.53–4.33). Based on our statistical data from each model, Model III
was the best ﬁtted model with the least AIC value (AIC = 669.102)
(Table 2).
Post-hoc power was calculated. We showed that given the hazard
ratio, sample size, follow-up period and median survival time with
alpha level at 0.05, the power was 0.88, 0.92 and 0.76 for age groups
1, 2 and 3, respectively.
4. Discussion
In this study, we evaluated the inﬂuence of different classiﬁcation
standards of age-groups on the prognosis of patients with high-grade
hemispheric glioma. We used a stringent statistical analysis to ﬁt all
three age-groups into different classiﬁcation models. (A) Age group 1:
≤45 years, 46–64 years, and ≥65 years; (B) age group 2: ≤50 years
and N50 years; and (C) age group 3: ≤60 years and N60 years. We
showed that the most appropriate classiﬁcation standard of age-
groups as an independent prognostic factor was age-group 2, and
50 years of age was the best cut-off point. We also showed that patho-
logical grade and regular chemotherapy regimenwere independent fac-
tors inﬂuencing OS of post-operative HGG patients.
A number of studies have investigated factors predicting OS in HGG
patients, since OS effectively reﬂects the prognosis of these patients.
There are conﬂicting data on the inﬂuence of gender on the prognosis
of HGG. Although some studies showed that gender was not a prognos-
tic factor, other data showed that gender had an impact on prognosis,
but was signiﬁcant only in univariate analyses [25–28]. A recent study
used univariate as well as multivariate analysis and identiﬁed female
gender as a signiﬁcant positive prognostic factor of OS in 64 HGG pa-
tients who received reirradiation at progression [29]. However, it is im-
portant to validate their data using a larger sample size. In the present
study, we used univariate analysis to show that females had a longer
median OS compared with males. However, gender was not a prognos-
tic factor in our multivariate analysis. We suggest that if future studies
conﬁrm a correlation between gender and prognosis of HGG, it will be
important to unravel the impact of hormones on the tumorigenesis of
glioma.
Using univariate and multivariate analyses, our present study
showed that higher pathological grade was an independent negative
prognostic factor for HGG patients. Our datawere consistentwith previ-
ous reports which identiﬁed pathological grade as an independent
prognostic factor associated with OS in HGG patients [30,31]. Although
radiation therapy has previously shown to have a relatively small im-
pact on OS of HGG patients [15], and there are conﬂicting data on the ef-
fects of post-operative adjuvant radiochemotherapy [6,32], in the
Table 2
Separate multivariate Cox regression models of age-groups with different cut-off points.
Model Ia Model II Model III Model IV
aHR (95% CI)b p aHR (95% CI) b p aHR (95% CI) b p aHR (95% CI) b p
Chemotherapy
Irregular vs. no 0.68 (0.42, 1.12) 0.134 0.64 (0.39, 1.07) 0.091 0.60 (0.36, 1.01) 0.053 0.69 (0.42, 1.14) 0.147
Regular vs. no 0.45 (0.25, 0.82) 0.009 0.42 (0.23, 0.76) 0.005 0.39 (0.22, 0.72) 0.002 0.40 (0.22, 0.73) 0.003
Pathological grade (IV vs. III) 3.71 (2.26, 6.10) b0.001 3.70 (2.22, 6.16) b0.001 4.01 (2.38, 6.74) b0.001 3.50 (2.12, 5.79) b0.001
Karnofsky Performance Scale 0.97 (0.96, 0.99) b0.001 0.97 (0.95, 0.99) b0.001 0.97 (0.96, 0.99) 0.001 0.97 (0.95, 0.99) b0.001
Age group 1
46–64 vs. ≤45 years 2.11 (1.29, 3.44) 0.003
≥65 vs. ≤45 years 3.28 (1.65, 6.50) b0.001
Age group 2
N50 vs. ≤50 years 2.74 (1.72, 4.35) b0.001
Age group 3
N60 vs. ≤60 years 2.57 (1.53, 4.33) b0.001
Model ﬁt statistics
AIC 685.709 675.302 669.102 676.467
Abbreviation: HR = adjusted hazard ratio; CI = conﬁdence interval; AIC = Akaike information criterion.
a Gender, chemotherapy, radiotherapy, grade and Karnofsky Performance Scale were entered initially. After backward selection procedure was performed, gender and radiotherapy
were excluded.
b HR and 95% CI were calculated by Cox regression analysis.
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signiﬁcantly longer OS in our univariate, but not multivariate analysis.
We suggest that our data on the signiﬁcance of radiation therapy were
not consistent with the results from the EORTC studies possibly because
our study did not use the HGG grade III and grade IV classiﬁcation sys-
tem based on the WHO criteria, It could also be because radiotherapy
of individual patients was performed at different medical centers,
resulting in a lack of uniform radiotherapy standards, and varying
accumulated doses for individual patients. It will be interesting to re-
evaluate the prognostic value of a uniform radiotherapy regimen in
these patients. The effect of adjuvant chemotherapy also remains un-
clear. Some studies showed that adjuvant chemotherapy was signiﬁ-
cantly correlated with prognosis [15,17], while other studies did not
observe this correlation [29,30]. Our present study demonstrated that
chemotherapy was a prognostic factor both in univariate and multivar-
iate analyses. Patients who received regular chemotherapy had signiﬁ-
cantly longer OS rates compared with those who received irregular or
no chemotherapy, even those who had received a full resection of
their high-grade glioma. Our data strongly suggested that HGG patients
should receive post-operative radiotherapy as well as chemotherapy to
maximize OS rates.
An early study suggesting that age was a prognostic factor for HGG
[33] was validated by other clinical studies which reported that age
was a signiﬁcant independent prognostic factor for glioma following
surgery [15,16,21,20]. However, there are conﬂicting data which show
that age is not a prognostic factor [17,22]. These conﬂicting data can
be explained by the fact that the classiﬁcation standards of age varied
between the different reports and the bias of age distribution were
very high, making it impossible to make objective conclusions. To the
best of our knowledge, there are no reports which have determined
the most appropriate standard of age-group classiﬁcation to evaluate
prognosis in HGG patients. In our present study, we adopted three dif-
ferent age classiﬁcation standards and performed a univariate analysis
to show that all three classiﬁcation standards served as prognostic fac-
tors. Ourmultivariate analysis showed that a higher agewas signiﬁcant-
ly associatedwith a higher risk of death.However, it is important to note
that the bias in the number of cases in age groups 1 and 3 was high,
while the groups classiﬁed as b50 and N50 had similar numbers of pa-
tients, suggesting that the impact of age bias can be excluded for age
group 2, and that our data for age group 2 were relatively objective.
The major limitations of our present study were the small sample size
and the fact that it was retrospective. We also did not differentiate the
different subgroupswithin the HGG groups based on histology. Another
limitation of this study was that we did not include patients who
underwent re-operation for recurrence. It is important to furthervalidate our resultswithmulticenter prospective studies on a large sam-
ple size.
In summary, we showed that age groups classiﬁed by age 50, chemo-
therapy, and pathological grade are independent factors inﬂuencingOS in
patients with HGG. Our data have important implications for the clinical
management of patients with high-grade hemispheric glioma.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.jns.2015.06.036.Conﬂict of interest
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